Tue, Sep 23, 2014, 5:44 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

mofisher22 835 posts  |  Last Activity: Sep 18, 2014 2:39 PM Member since: Mar 26, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Is WMT still being considered as a buyer of RAD?

    by mofisher22 Sep 18, 2014 1:29 PM
    mofisher22 mofisher22 Sep 18, 2014 2:39 PM Flag

    wallst, do you really believe there was no basis at all for the WMT buyout talk? I recall some writers on SA mentioning the possiblity, and it seems very plausible and good for WMT. It would allow them so many more locations in which people could get meds. I think many people prefer going to a neighborhood drug store rather than a huge Walmart to pick up their meds.I am thinking this beaten down sp might get WMT thinking seriously about it. Today RAD is 20% off yesterdays price, and could even go lower in coming days.

  • I owned RAD from Dec, 2012 til April,2014, and I recall there was a lot of speculation that WMT might buy RAD. Sorry to see todays sell off, I enjoyed a great $1 to $7 16 month run up. In hindsight, as some here speculated, maybe it was too far too fast. Good to see Ace made it thru his couple years of misery, now he has something to lift his spirits. I guess he will stay down on RAD til his dying day, got to give him credit, he is not a quitter.

  • I am pretty experienced in beaten down bios, I sense this one could hit $3 or $4 or more in the coming year. Any thoughts?

  • I am former holder, memphian, and wondering what the consensus is here? I know a lot of cash has evaporated over the past several years. Is this maybe a bottom? Just trying to see what is going on.

  • Reply to


    by henryruby88888 Jun 30, 2014 9:52 AM
    mofisher22 mofisher22 Jul 8, 2014 10:17 PM Flag

    henry, u got 2 of 3 right, but the American lifestyle does not appreciate the low effectiveness of belviq. Sad fact is, the fast food industry and learned diet of Americans will not allow a pill that does not allow their normal foods. It is hard to beat MuD, taco bell, and pixxa hut, and lots more.

  • Reply to

    I margin bought 25,000 shares @ $7.00

    by stockjimmy2014 Jun 29, 2014 5:08 PM
    mofisher22 mofisher22 Jun 29, 2014 9:26 PM Flag

    jimmy, you were about 1 year and $5 late to the RAD party. Selling on Monday may be a good idea.

  • Reply to

    This stock is Synful

    by mofisher22 May 30, 2014 8:11 PM
    mofisher22 mofisher22 Jun 2, 2014 1:35 PM Flag

    yoda, back in April, I finally figured out that in bio tech, it is like gambling at casino, if you dont quit when you are ahead, u are doomed to lose. So, after a 53% portfolio gain last year, and 12 % ytd in 2014 in late March, a 65% 15 month gain, I sold it all and went to cash. The only way to win in biotech is play the run up, it is like a pyrimid scheme, u got to get in early, then get out with profit and leave the late comers holding the bag. SYN is perfect example, early birds got in at round a buck in Dec., sold at $3 in March, made 200% gain, while latecomers were buying the hype for the news in April, which we all know what happened. I just dont need the stress anymore, I am going strictly low cost index funds, some sector funds, and cash. Oh, I must admit I may buy one bio now and then, got back in ONCS today. Feels good to have a little potential action.

  • Reply to

    This stock is Synful

    by mofisher22 May 30, 2014 8:11 PM
    mofisher22 mofisher22 May 31, 2014 10:47 PM Flag

    guys, I rode ONCS from 35 to 85, it has hung well, I suspect it may move up

  • Reply to

    This stock is Synful

    by mofisher22 May 30, 2014 8:11 PM
    mofisher22 mofisher22 May 31, 2014 5:01 PM Flag

    I understand how you folks feel, and if you believe in something, stick with it. But, it does not make sense to me that if they really had something, that insiders would sell. Guess I am jaded after being burned on several bio techs that had similar chart reaction to so called positive news.

  • mofisher22 by mofisher22 May 30, 2014 8:11 PM Flag

    just checked it, sold at $3 for a double in April, this must be a pump and dump. I thought their news was good in late April? Why such a drop?

  • Based on Don's rec on another board, I got in at 1.10, back in Dec., the offering and the Kirk investment were incentives for me. I rode up to 3.50, but sold on the way down at $3. At the time, mid to late March, I had had a great ytd return, 20%, while the indexes were flat. In 3 days, my portfolio dropped 8%, so I dumped all and got out with a 12% ytd, and 65% 15 month gain. I have tried to avoid looking at finance stock news, but tonight I looked and say SYN under $1.40, meaning if I held, I would have lost $8,000 on it , and prob. $100,000 on my total, as several other of my previous holdings I now see have dropped huge. What has happened here and bio tech in general? I just saw where Endocyte had dropped from $28 to $6. I am thankful I got out when I did.

  • after looking at 1 year chart, I am relieved I left 2 years ago. Anyone holding the bag, I feel sorry for. glta

  • with $4 million in revenue? This is another in the long list of biotechs, ie, DNDN, ARIA, HZNP, etc., , in which wise money dumps at the false top, leaving others to hold the bag. Any KERX holders here?

  • Amazing, what do they have in their "lock box"? I would think if anything worthwhile, big pharma would have bought long ago. Also, I suspect there is a lot of bag holders here, and may be many more on the ride back down. JMO

  • Reply to


    by fanelli_robert Apr 8, 2014 3:47 PM
    mofisher22 mofisher22 Apr 8, 2014 10:45 PM Flag

    thanks, Robert

  • Reply to

    Observations from a departed long,

    by mofisher22 Apr 8, 2014 9:18 PM
    mofisher22 mofisher22 Apr 8, 2014 10:37 PM Flag

    Do not buy into message board and SA pie in the sky pumpers, Do not keep riding a broken down horse, when a stock with an approved drug that was supposed to be its messiah, during a 4 month bull market for its sector, went south, it is time to wake up and smell the roses. ginny, best of luck to you, but I suggest you become a realist, instead of an idealist, I suspect it may save you money going forward, jmo

  • Have not posted here in several weeks, about 3 weeks ago, I went basically all cash, did keep ROX, NLST, and SYMX, 3 non biotech spec stocks. Was able to couple last years humongous gains with a 12 % gain for 2014. As I have thought for years, for other than conservative, big cap, dividend paying stocks, the investment in small cap stocks, especially bio techs, is no different than a casino, huge gains in a short while, then, like many people in casinos do, huge losses in a short time. Anyone using normal attributes such as product sales, potential sales, etc. is somewhat clueless in how those markets work. In most small cap drug stocks, the money is made way before any sort of approval is reached. An example, I rode MNKD up from $2 to $8 in 2013, and thankfully got out above $7. After ADCOM approval, it never even reached near the $8.79 of 2013, and now has dropped even more. SYN, a stock I bought last DEC. at $1.10, and avg. at app. $1.60, ran to $3.60 less than a month ago, and is now down about 40% off that price. Nothing has changed in their situation. But, before the max run up, they did say they were announcing results of a crucial trial I think in April. Well, I owned CYTK, which did the same thing last year. Everybody thought, well, the news must be good when they announce the results at the conference, but , guess what, people found loop holds in their results. It appears the bad news has already leaked on SYN, though many are still holding out hope for the news next month. Face it, if the news was going to be great, I imagine plenty folks in the loop would be propping the price up with buys. So, back to ATRS, if the sp was $6 way before approval, and now after approval, it is about half that, what does that tell you? /Among others, the main lesson here is do not fall in love with a stock. Like a few others here who bailed and bought HZNP, INO, SYN, RAD and a few others, the last 15 months proved bountiful. I am pleased to say I am out, GLTA longs.

  • Reply to


    by fanelli_robert Apr 8, 2014 3:47 PM
    mofisher22 mofisher22 Apr 8, 2014 7:48 PM Flag

    robert, I am pretty much totally in cash, I had a 20% ytd gain on app. March 20, then a week later, it was down to 12%, so I figured that would be a good year after a great year last year, am happy with a 12% yeat. However, I am still holding SYMX, NLST, and ROX, three spec stocks, still very low priced, and outside the bio tech sector. All 3 have held up well during the Nasdaq/bio tech collapse. I know you commented on them a few weeks ago, do you have any current thoughts? I feel they have very little downside, and expect at least 1, or hopefully 2 to make a nice move up, a double, triple or more this year.

  • Reply to


    by goutah3006 Apr 5, 2014 12:42 PM
    mofisher22 mofisher22 Apr 5, 2014 11:10 PM Flag

    long time bio investor and winner/loser. After being up 20 % ytd, in mid march, dumped all a week later at 11 % gain, thankfully, would otherwise be in red today. From my experience, the best way to make money in bios is to buy when they get sold off due to events, then gradually sell off with profits. HALO is a good example, if you look at 3 year chart, you see numerous big dips, after nice run ups. PRAN is also a good example. glta

  • It may be for the good, but I bailed on this at $2, and most other spec stocks. But, these offerings can sure beat a person down, especially if they seddenly turn red in their portfolio. Justsaw it on list of losers, glta, it does seem to have a viable future, I am just too tired to continue.

3.75+0.10(+2.74%)Sep 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.